Dick Menzies

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7947742/publications.pdf

Version: 2024-02-01

200	17,687	18436 62	14156 128
papers	citations	h-index	g-index

205	205	205	14816
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Four months of rifampicin monotherapy for latent tuberculosis infection in children. Clinical and Experimental Pediatrics, 2022, 65, 214-221.	0.9	6
2	Scaling up investigation and treatment of household contacts of tuberculosis patients in Brazil: a cost-effectiveness and budget impact analysis. The Lancet Regional Health Americas, 2022, 8, 100166.	1.5	5
3	Concise Clinical Review of Hematologic Toxicity of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Role of Mitochondria. Tuberculosis and Respiratory Diseases, 2022, 85, 111-121.	0.7	8
4	Chapter 5: Treatment of tuberculosis disease. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2022, 6, 66-76.	0.2	3
5	Chapter 4: Diagnosis of tuberculosis infection. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2022, 6, 49-65.	0.2	3
6	Chapter 8: Drug-resistant tuberculosis. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2022, 6, 109-128.	0.2	1
7	Chapter 6: Tuberculosis preventive treatment in adults. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2022, 6, 77-86.	0.2	2
8	Safety of prolonged treatment with bedaquiline in programmatic conditions. ERJ Open Research, 2022, 8, 00685-2021.	1.1	5
9	Modeling treatment effect modification in multidrug-resistant tuberculosis in an individual patientdata meta-analysis. Statistical Methods in Medical Research, 2022, 31, 689-705.	0.7	3
10	Low Body Mass Index at Treatment Initiation and Rifampicin-Resistant Tuberculosis Treatment Outcomes: An Individual Participant Data Meta-Analysis. Clinical Infectious Diseases, 2022, 75, 2201-2210.	2.9	5
11	Systematic on-site testing for SARS-CoV-2 infection among asymptomatic essential workers in MontrÃ©al, Canada: a prospective observational and cost-assessment study. CMAJ Open, 2022, 10, E409-E419.	1.1	2
12	Adequacy of Serial Self-performed SARS-CoV-2 Rapid Antigen Detection Testing for Longitudinal Mass Screening in the Workplace. JAMA Network Open, 2022, 5, e2210559.	2.8	18
13	Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study. Lancet Infectious Diseases, The, 2022, 22, 1042-1051.	4.6	28
14	Aminoglycosides and Capreomycin in the Treatment of Multidrug-resistant Tuberculosis: Individual Patient Data Meta-analysis of 12 030 Patients From 25 Countries, 2009â€“2016. Clinical Infectious Diseases, 2021, 73, e3929-e3936.	2.9	19
15	Comparing the Diagnostic Performance of QuantiFERON-TB Gold Plus to Other Tests of Latent Tuberculosis Infection: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2021, 73, e1116-e1125.	2.9	27
16	Effects of programmatic interventions to improve the management of latent tuberculosis: a follow up study up to five months after implementation. BMC Public Health, 2021, 21, 177.	1.2	2
17	Build back better: Advances in tuberculosis research in Canada & globally in 2020. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2021, 5, 121-124.	0.2	0
18	The Sensitivity and Costs of Testing for SARS-CoV-2 Infection With Saliva Versus Nasopharyngeal Swabs. Annals of Internal Medicine, 2021, 174, 501-510.	2.0	160

#	Article	IF	Citations
19	Effectiveness and cost-effectiveness of a health systems intervention for latent tuberculosis infection management (ACT4): a cluster-randomised trial. Lancet Public Health, The, 2021, 6, e272-e282.	4.7	18
20	Acceptability, feasibility, and impact of a pilot tuberculosis literacy and treatment counselling intervention: a mixed methods study. BMC Infectious Diseases, 2021, 21, 449.	1.3	3
21	Tuberculosis active case-finding: looking for cases in all the right places?. Lancet Public Health, The, 2021, 6, e261-e262.	4.7	4
22	Effectiveness of germicidal ultraviolet light to inactivate coronaviruses on personal protective equipment to reduce nosocomial transmission. Infection Control and Hospital Epidemiology, 2021, , 1-6.	1.0	4
23	The latent tuberculosis cascade-of-care among people living with HIV: A systematic review and meta-analysis. PLoS Medicine, 2021, 18, e1003703.	3.9	21
24	Tuberculosis preventive treatment in people living with HIVâ€"Is the glass half empty or half full?. PLoS Medicine, 2021, 18, e1003702.	3.9	4
25	Evidence-based Definition for Extensively Drug-Resistant Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 713-722.	2.5	22
26	Economic and modeling evidence for tuberculosis preventive therapy among people living with HIV: A systematic review and meta-analysis. PLoS Medicine, 2021, 18, e1003712.	3.9	19
27	Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis. PLoS Medicine, 2021, 18, e1003738.	3.9	18
28	Quantifying the rates of late reactivation tuberculosis: a systematic review. Lancet Infectious Diseases, The, 2021, 21, e303-e317.	4.6	19
29	Reply to van Deun and Decroo. Clinical Infectious Diseases, 2021, 72, e1168-e1169.	2.9	1
30	Evaluating the performance of propensity score matching based approaches in individual patient data meta-analysis. BMC Medical Research Methodology, 2021, 21, 257.	1.4	6
31	What makes a score a winner?. Lancet Infectious Diseases, The, 2020, 20, 10-11.	4.6	0
32	Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. Lancet Infectious Diseases, The, 2020, 20, 318-329.	4.6	37
33	Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. European Respiratory Journal, 2020, 55, 1901467.	3.1	55
34	Estimating treatment importance in multidrugâ€resistant tuberculosis using Targeted Learning: An observational individual patient data network metaâ€analysis. Biometrics, 2020, 76, 1007-1016.	0.8	7
35	Chest x-ray analysis with deep learning-based software as a triage test for pulmonary tuberculosis: a prospective study of diagnostic accuracy for culture-confirmed disease. The Lancet Digital Health, 2020, 2, e573-e581.	5.9	76
36	Can BCG be useful to mitigate the COVID-19 pandemic? A Canadian perspective. Canadian Journal of Public Health, 2020, 111, 939-944.	1.1	3

#	Article	IF	Citations
37	Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings. Annals of Internal Medicine, 2020, 173, 169-178.	2.0	20
38	Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis. Lancet, The, 2020, 396, 402-411.	6.3	49
39	Active testing of groups at increased risk of acquiring SARS-CoV-2 in Canada: costs and human resource needs. Cmaj, 2020, 192, E1146-E1155.	0.9	30
40	Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials. Clinical Infectious Diseases, 2020, 73, e3545-e3554.	2.9	19
41	Solutions to improve the latent tuberculosis Cascade of Care in Ghana: a longitudinal impact assessment. BMC Infectious Diseases, 2020, 20, 352.	1.3	8
42	Reply to Chang and Yew. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 778-779.	2.5	0
43	Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial. BMJ Open, 2020, 10, e033945.	0.8	33
44	Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respiratory Medicine,the, 2020, 8, 383-394.	5.2	155
45	Advances in tuberculosis in 2019 in Canada and globally. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, S34-S37.	0.2	0
46	Guidelines for the treatment of latent tuberculosis infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. American Journal of Transplantation, 2020, 20, 1196-1206.	2.6	31
47	Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant Tuberculosis. Emerging Infectious Diseases, 2020, 26, .	2.0	10
48	Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ, The, 2020, 370, m2516.	3.0	673
49	Changes in treatment for multidrug-resistant tuberculosis according to national income. European Respiratory Journal, 2020, 56, 2001394.	3.1	4
50	Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs. European Respiratory Journal, 2020, 55, 1902048.	3.1	31
51	Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis. BMJ, The, 2020, 368, m549.	3.0	58
52	Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0241536.	1.1	250
53	Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recommendations and Reports, 2020, 69, 1-11.	26.7	262
54	Title is missing!. , 2020, 15, e0241536.		0

#	Article	IF	Citations
55	Title is missing!. , 2020, 15, e0241536.		0
56	Title is missing!. , 2020, 15, e0241536.		0
57	Title is missing!. , 2020, 15, e0241536.		0
58	Multidrug-resistant tuberculosis â€“ Authors' reply. Lancet, The, 2019, 394, 299-300.	6.3	2
59	Knowledge, attitudes and practices on tuberculosis transmission and prevention among auxiliary healthcare professionals in three Brazilian high-burden cities: a cross-sectional survey. BMC Health Services Research, 2019, 19, 532.	0.9	14
60	Disrupting a cycle of mistrust: A constructivist grounded theory study on patient-provider trust in TB care. Social Science and Medicine, 2019, 240, 112578.	1.8	16
61	A systematic review of the diagnostic accuracy of artificial intelligence-based computer programs to analyze chest x-rays for pulmonary tuberculosis. PLoS ONE, 2019, 14, e0221339.	1.1	113
62	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. Lancet Respiratory Medicine,the, 2019, 7, 820-826.	5.2	92
63	The impact of improved detection and treatment of isoniazid resistant tuberculosis on prevalence of multi-drug resistant tuberculosis: A modelling study. PLoS ONE, 2019, 14, e0211355.	1.1	8
64	The mTST â€“ An mHealth approach for training and quality assurance of tuberculin skin test administration and reading. PLoS ONE, 2019, 14, e0215240.	1.1	9
65	Enhancing the public health impact of latent tuberculosis infection diagnosis and treatment (ACT4): protocol for a cluster randomised trial. BMJ Open, 2019, 9, e025831.	0.8	18
66	Is there a fundamental flaw in Canadaâ€™s post-arrival immigrant surveillance system for tuberculosis?. PLoS ONE, 2019, 14, e0212706.	1.1	13
67	Latent tuberculosis infection in healthcare workers in low- and middle-income countries: an updated systematic review. European Respiratory Journal, 2019, 53, 1801789.	3.1	52
68	Intestinal dysbiosis compromises alveolar macrophage immunity to Mycobacterium tuberculosis. Mucosal Immunology, 2019, 12, 772-783.	2.7	65
69	No evidence of increased risk of acquired rifampin resistance. Cmaj, 2019, 191, E1314-E1315.	0.9	1
70	Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2019, 200, e93-e142.	2.5	282
71	Asthma phenotypes based on health services use for allergic diseases in a province-wide birth cohort. Annals of Allergy, Asthma and Immunology, 2019, 122, 50-57.e2.	0.5	6
72	Predicting tuberculosis relapse in patients treated with the standard 6-month regimen: an individual patient data meta-analysis. Thorax, 2019, 74, 291-297.	2.7	41

#	Article	IF	Citations
73	Causal inference with multiple concurrent medications: A comparison of methods and an application in multidrug-resistant tuberculosis. Statistical Methods in Medical Research, 2019, 28, 3534-3549.	0.7	13
74	Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review. European Respiratory Journal, 2019, 53, 1801030.	3.1	38
75	Whatâ€™s Next for the Standard Short-Course Regimen for Treatment of Multidrug-Resistant Tuberculosis. American Journal of Tropical Medicine and Hygiene, 2019, 100, 229-230.	0.6	2
76	Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respiratory Medicine,the, 2018, 6, 265-275.	5.2	80
77	Determinants of tuberculosis trends in six Indigenous populations of the USA, Canada, and Greenland from 1960 to 2014: a population-based study. Lancet Public Health, The, 2018, 3, e133-e142.	4.7	25
78	New short regimens for latent tuberculosis treatment: safety first!. European Respiratory Journal, 2018, 52, 1802180.	3.1	5
79	Using a quality improvement approach to improve care for latent tuberculosis infection. Expert Review of Anti-Infective Therapy, 2018, 16, 737-747.	2.0	6
80	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, The, 2018, 392, 821-834.	6.3	452
81	Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. New England Journal of Medicine, 2018, 379, 440-453.	13.9	267
82	Safety and Side Effects of Rifampin versus Isoniazid in Children. New England Journal of Medicine, 2018, 379, 454-463.	13.9	124
83	Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. PLoS Medicine, 2018, 15, e1002591.	3.9	96
84	Knowledge and perceptions of tuberculosis transmission and prevention among physicians and nurses in three Brazilian capitals with high incidence of tuberculosis. Jornal Brasileiro De Pneumologia, 2018, 44, 168-170.	0.4	7
85	Risk of Active Tuberculosis in Patients with Cancer: A Systematic Review and Meta-Analysis. Clinical Infectious Diseases, 2017, 64, ciw838.	2.9	73
86	Finding the right dose of rifampicin, and the right dose of optimism. Lancet Infectious Diseases, The, 2017, 17, 2-3.	4.6	5
87	Emergence of drug resistance in patients with tuberculosis cared for by the Indian health-care system: a dynamic modelling study. Lancet Public Health, The, 2017, 2, e47-e55.	4.7	33
88	Isoniazid-resistant tuberculosis treatment with first-line drugsâ€“Author reply. Lancet Infectious Diseases, The, 2017, 17, 260.	4.6	0
89	Drug-Resistant Tuberculosis. , 2017, , 263-286.		0
90	Association Between Bacillus Calmette-GuÃ©rin Vaccination and Childhood Asthma in the Quebec Birth Cohort on Immunity and Health. American Journal of Epidemiology, 2017, 186, 344-355.	1.6	14

#	Article	IF	Citations
91	An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis. European Respiratory Journal, 2017, 49, 1600803.	3.1	83
92	Effect of Intermittency on Treatment Outcomes in Pulmonary Tuberculosis: An Updated Systematic Review and Metaanalysis. Clinical Infectious Diseases, 2017, 64, 1211-1220.	2.9	25
93	Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis. European Respiratory Journal, 2017, 49, 1600993.	3.1	20
94	Effectiveness of Canada's tuberculosis surveillance strategy in identifying immigrants at risk of developing and transmitting tuberculosis: a population-based retrospective cohort study. Lancet Public Health, The, 2017, 2, e450-e457.	4.7	24
95	Bacillus Calmette-GuÃ©rin (BCG) vaccination patterns in the province of QuÃ©bec, Canada, 1956â€“1974. Vaccine, 2017, 35, 4777-4784.	1.7	10
96	Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses. European Respiratory Journal, 2017, 50, 1700061.	3.1	83
97	Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2017, 17, 223-234.	4.6	196
98	Knowledge about tuberculosis transmission and prevention and perceptions of health service utilization among index cases and contacts in Brazil: Understanding losses in the latent tuberculosis cascade of care. PLoS ONE, 2017, 12, e0184061.	1.1	19
99	Reply to Dobler. Clinical Infectious Diseases, 2017, 65, 1423-1424.	2.9	0
100	The impact of the Brazilian family health on selected primary care sensitive conditions: A systematic review. PLoS ONE, 2017, 12, e0182336.	1.1	76
101	Tuberculosis transmission in the Indigenous peoples of the Canadian prairies. PLoS ONE, 2017, 12, e0188189.	1.1	7
102	Current Options in Treatment and Issues in Tuberculosis Care in Low- and Middle-Income Countries. , 2017, , 99-116.		0
103	Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis. PLoS ONE, 2016, 11, e0151724.	1.1	12
104	Housing and tuberculosis in an Inuit village in northern Quebec: a case-control study. CMAJ Open, 2016, 4, E496-E506.	1.1	16
105	Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. European Respiratory Journal, 2016, 48, 1160-1170.	3.1	27
106	The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2016, 16, 1269-1278.	4.6	334
107	Treatment of human disease due to Mycobacterium bovis: a systematic review. European Respiratory Journal, 2016, 48, 1500-1503.	3.1	23
108	Putting numbers on the End TB Strategyâ€”an impossible dream?. The Lancet Global Health, 2016, 4, e764-e765.	2.9	3

#	Article	IF	Citations
109	Predictors of hospitalization of tuberculosis patients in Montreal, Canada: a retrospective cohort study. BMC Infectious Diseases, 2016, 16, 679.	1.3	12
110	Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis. Clinical Infectious Diseases, 2016, 62, 887-895.	2.9	64
111	Serial interferon-gamma release assays for latent tuberculosis in dialysis patients with end stage renal disease in a Korean population. BMC Infectious Diseases, 2015, 15, 381.	1.3	10
112	Reemergence and Amplification of Tuberculosis in the Canadian Arctic. Journal of Infectious Diseases, 2015, 211, 1905-1914.	1.9	78
113	Modeling the impact of tuberculosis interventions on epidemiologic outcomes and health system costs. BMC Public Health, 2015, 15, 141.	1.2	11
114	Reply to Wang and Zhang. Clinical Infectious Diseases, 2015, 60, 1286-1287.	2.9	0
115	Inadequate Diet is Associated with AcquiringMycobacterium tuberculosisInfection in an Inuit Community: A Case-Control Study. Annals of the American Thoracic Society, 2015, 12, 150622133645008.	1.5	21
116	The impact of tuberculosis on health utility: a longitudinal cohort study. Quality of Life Research, 2015, 24, 1337-1349.	1.5	11
117	Fluoroquinolone Therapy for the Prevention of Multidrug-Resistant Tuberculosis in Contacts. A Cost-Effectiveness Analysis. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 229-237.	2.5	28
118	Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in children: a systematic review and meta-analysis. Lancet Respiratory Medicine,the, 2015, 3, 451-461.	5.2	246
119	Management of latentMycobacterium tuberculosisinfection: WHO guidelines for low tuberculosis burden countries. European Respiratory Journal, 2015, 46, 1563-1576.	3.1	475
120	Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment. European Respiratory Journal, 2015, 46, 1461-1470.	3.1	39
121	Population genomics ofMycobacterium tuberculosisin the Inuit. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13609-13614.	3.3	77
122	Health-related quality of life and tuberculosis: a longitudinal cohort study. Health and Quality of Life Outcomes, 2015, 13, 65.	1.0	37
123	Drug-Resistant Tuberculosis. , 2014, , 1-20.		0
124	Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis. Clinical Infectious Diseases, 2014, 59, 1364-1374.	2.9	116
125	Looking for TB in the sky: Money well spent?. Travel Medicine and Infectious Disease, 2014, 12, 3-4.	1.5	0
126	Comparing cost-effectiveness of standardised tuberculosis treatments given varying drug resistance. European Respiratory Journal, 2014, 43, 566-581.	3.1	17

#	Article	IF	Citations
127	Undernutrition and the incidence of tuberculosis in India: national and subnational estimates of the population-attributable fraction related to undernutrition. The National Medical Journal of India, 2014, 27, 128-33.	0.1	47
128	A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis. Infectious Diseases and Therapy, 2013, 2, 123-144.	1.8	92
129	Molecular methods for tuberculosis trials: time for whole-genome sequencing?. Lancet Respiratory Medicine,the, 2013, 1, 759-761.	5.2	4
130	Trajectories of tuberculosis-specific interferon-gamma release assay responses among medical and nursing students in rural India. Journal of Epidemiology and Global Health, 2013, 3, 105.	1.1	14
131	Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. European Respiratory Journal, 2013, 42, 169-179.	3.1	226
132	Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. European Respiratory Journal, 2013, 42, 156-168.	3.1	346
133	How Methodologic Differences Affect Results of Economic Analyses: A Systematic Review of Interferon Gamma Release Assays for the Diagnosis of LTBI. PLoS ONE, 2013, 8, e56044.	1.1	23
134	Repeat IGRA Testing in Canadian Health Workers: Conversions or Unexplained Variability?. PLoS ONE, 2013, 8, e54748.	1.1	63
135	Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. PLoS Medicine, 2012, 9, e1001300.	3.9	430
136	An Updated Systematic Review and Meta-analysis on the Treatment of Active Tuberculosis in Patients With HIV Infection. Clinical Infectious Diseases, 2012, 55, 1154-1163.	2.9	70
137	Hammering the point home: serologic testing costs more and harms more patients than other strategies for the diagnosis of active tuberculosis in India. Evidence-Based Medicine, 2012, 17, 58-59.	0.6	2
138	Predictive value of interferon-Î³ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2012, 12, 45-55.	4.6	441
139	TB Screening in Canadian Health Care Workers Using Interferon-Gamma Release Assays. PLoS ONE, 2012, 7, e43014.	1.1	30
140	Treatment of latent TB: first do no harm. Expert Review of Anti-Infective Therapy, 2011, 9, 491-493.	2.0	6
141	Drug-Resistant Tuberculosis. Drugs, 2011, 71, 815-825.	4.9	16
142	Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection. New England Journal of Medicine, 2011, 365, 2155-2166.	13.9	769
143	Developing a Tuberculosis Transmission Model That Accounts for Changes in Population Health. Medical Decision Making, 2011, 31, 53-68.	1.2	10
144	Fatores associados ao atraso no diagnÃ³stico da tuberculose pulmonar no estado do Rio de Janeiro. Jornal Brasileiro De Pneumologia, 2011, 37, 512-520.	0.4	50

#	Article	IF	Citations
145	Treatment of drug-resistant tuberculosis. Infection and Drug Resistance, 2011, 4, 129.	1.1	30
146	Therapeutic Drug Monitoring in the Treatment of Active Tuberculosis. Canadian Respiratory Journal, 2011, 18, 225-229.	0.8	58
147	Reduced Transmissibility of East African Indian Strains of Mycobacterium tuberculosis. PLoS ONE, 2011, 6, e25075.	1.1	63
148	Tuberculosis: evidence review for newly arriving immigrants and refugees. Cmaj, 2011, 183, E939-E951.	0.9	85
149	Adverse events associated with treatment of latent tuberculosis in the general population. Cmaj, 2011, 183, E173-E179.	0.9	51
150	The BCG World Atlas: A Database of Global BCG Vaccination Policies and Practices. PLoS Medicine, 2011, 8, e1001012.	3.9	479
151	Recent developments in treatment of latent tuberculosis infection. Indian Journal of Medical Research, 2011, 133, 257-66.	0.4	27
152	Occupational respiratory infections. Current Opinion in Pulmonary Medicine, 2010, 16, 1.	1.2	11
153	Treatment of latent tuberculosis infection: An update. Respirology, 2010, 15, 603-622.	1.3	167
154	Saudi guidelines for testing and treatment of latent tuberculosis infection. Annals of Saudi Medicine, 2010, 30, 38.	0.5	39
155	Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Thorax, 2010, 65, 582-587.	2.7	47
156	Treatment of Active Tuberculosis in HIVâ€Coinfected Patients: A Systematic Review and Metaâ€Analysis. Clinical Infectious Diseases, 2010, 50, 1288-1299.	2.9	158
157	Occupation-Related Respiratory Infections Revisited. Infectious Disease Clinics of North America, 2010, 24, 655-680.	1.9	4
158	Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet, The, 2010, 375, 1920-1937.	6.3	404
159	Patients' Costs and Cost-Effectiveness of Tuberculosis Treatment in DOTS and Non-DOTS Facilities in Rio de Janeiro, Brazil. PLoS ONE, 2010, 5, e14014.	1.1	70
160	Recommendations on Interferon Gamma Release Assaysfor the Diagnosis of Latent Tuberculosis Infectionâ€"2010 Update. Canada Communicable Disease Report, 2010, 36, 1-22.	0.6	23
161	Saudi guidelines for testing and treatment of latent tuberculosis infection. Annals of Saudi Medicine, 2010, 30, 38-49.	0.5	2
162	Standardized Treatment of Active Tuberculosis in Patients with Previous Treatment and/or with Mono-resistance to Isoniazid: A Systematic Review and Meta-analysis. PLoS Medicine, 2009, 6, e1000150.	3.9	159

#	Article	IF	Citations
163	Effect of Duration and Intermittency of Rifampin on Tuberculosis Treatment Outcomes: A Systematic Review and Meta-Analysis. PLoS Medicine, 2009, 6, e1000146.	3.9	169
164	Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 273-280.	2.5	247
165	Tuberculosis screening of travelers to higher-incidence countries: A cost-effectiveness analysis. BMC Public Health, 2008, 8, 201.	1.2	15
166	Influence of Multidrug Resistance on Tuberculosis Treatment Outcomes with Standardized Regimens. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 306-312.	2.5	67
167	Predicting Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1055-1057.	2.5	20
168	Challenges to Tuberculin Screening and Follow-up in an Urban Aboriginal Sample in Montreal, Canada. Journal of Health Care for the Poor and Underserved, 2008, 19, 369-379.	0.4	6
169	Systematic Review: T-Cellâ€"based Assays for the Diagnosis of Latent Tuberculosis Infection: An Update. Annals of Internal Medicine, 2008, 149, 177.	2.0	1,122
170	Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection. Annals of Internal Medicine, 2008, 149, 689.	2.0	180
171	Initial Drug Resistance and Tuberculosis Treatment Outcomes: Systematic Review and Meta-analysis. Annals of Internal Medicine, 2008, 149, 123.	2.0	151
172	T-Cell Assays for Tuberculosis Infection: Deriving Cut-Offs for Conversions Using Reproducibility Data. PLoS ONE, 2008, 3, e1850.	1.1	89
173	Costs for Tuberculosis Care in Canada. Canadian Journal of Public Health, 2008, 99, 391-396.	1.1	28
174	Meta-analysis: New Tests for the Diagnosis of Latent Tuberculosis Infection: Areas of Uncertainty and Recommendations for Research. Annals of Internal Medicine, 2007, 146, 340.	2.0	874
175	Adverse reactions to first-line antituberculosis drugs. Expert Opinion on Drug Safety, 2006, 5, 231-249.	1.0	256
176	The Long-term Health and Economic Benefits of DOTS Implementation in Ecuador. Canadian Journal of Public Health, 2006, 97, 14-19.	1.1	4
177	Dwellings, crowding, and tuberculosis in Montreal. Social Science and Medicine, 2006, 63, 501-511.	1.8	49
178	Impact of DOTS expansion on tuberculosis related outcomes and costs in Haiti. BMC Public Health, 2006, 6, 209.	1.2	23
179	Serial Testing of Health Care Workers for Tuberculosis Using Interferon-Î³ Assay. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 349-355.	2.5	255
180	Tuberculosis among Health-Care Workers in Low- and Middle-Income Countries: A Systematic Review. PLoS Medicine, 2006, 3, e494.	3.9	422

#	Article	IF	Citations
181	Building-Related Illnesses. , 2006, , 737-783.		3
182	Microbial Contamination in Airplane Cabins:Health Effects and Remediation. The Handbook of Environmental Chemistry Volume 4, 2005, , 151-167.	0.0	2
183	Domestic Returns from Investment in the Control of Tuberculosis in Other Countries. New England Journal of Medicine, 2005, 353, 1008-1020.	13.9	136
184	Treatment Completion and Costs of a Randomized Trial of Rifampin for 4 Months versus Isoniazid for 9 Months. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 445-449.	2.5	155
185	Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 1472-1477.	2.5	681
186	Efficacy of Environmental Measures in Reducing Potentially Infectious Bioaerosols During Sputum Induction. Infection Control and Hospital Epidemiology, 2003, 24, 483-489.	1.0	18
187	Effect of ultraviolet germicidal lights installed in office ventilation systems on workers' health and wellbeing: double-blind multiple crossover trial. Lancet, The, 2003, 362, 1785-1791.	6.3	111
188	Factors Associated with Tuberculin Conversion in Canadian Microbiology and Pathology Workers. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 599-602.	2.5	26
189	Screening immigrants to Canada for tuberculosis: chest radiography or tuberculin skin testing?. Cmaj, 2003, 169, 1035-6.	0.9	6
190	Delay in Diagnosis among Hospitalized Patients with Active Tuberculosisâ€"Predictors and Outcomes. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 927-933.	2.5	172
191	Hospital Ventilation and Risk for Tuberculous Infection in Canadian Health Care Workers. Annals of Internal Medicine, 2000, 133, 779.	2.0	165
192	Comparison of Cost-Effectiveness of Tuberculosis Screening of Close Contacts and Foreign-Born Populations. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 2079-2086.	2.5	122
193	Tuberculosis Screening of Immigrants to Low-Prevalence Countries. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 780-789.	2.5	100
194	Interpretation of Repeated Tuberculin Tests. American Journal of Respiratory and Critical Care Medicine, 1999, 159, 15-21.	2.5	459
195	Aeroallergens and work-related respiratory symptoms among office workers. Journal of Allergy and Clinical Immunology, 1998, 101, 38-44.	1.5	52
196	Impact of Immigration on Tuberculosis Infection Among Canadian-born Schoolchildren and Young Adults in Montreal. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 1915-1921.	2.5	27
197	Building-Related Illnesses. New England Journal of Medicine, 1997, 337, 1524-1531.	13.9	135
198	Effect of a New Ventilation System on Health and Well-Being of Office Workers. Archives of Environmental Health, 1997, 52, 360-367.	0.4	42

#	Article	IF	Citations
199	Issues in the Management of Contacts of Patients with Active Pulmonary Tuberculosis. Canadian Journal of Public Health, 1997, 88, 197-201.	1.1	30
200	Tuberculosis among Health Care Workers. New England Journal of Medicine, 1995, 332, 92-98.	13.9	331